Literature DB >> 29927572

Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds.

Monika Raab1, Mourad Sanhaji1, Larissa Pietsch2,3, Isabelle Béquignon2, Amanda K Herbrand2, Evelyn Süß2, Santosh L Gande4,3, Birgit Caspar4, Denis Kudlinzki4,3, Krishna Saxena4, Sridhar Sreeramulu4, Harald Schwalbe4,3, Klaus Strebhardt1,3, Ricardo M Biondi2,3,5.   

Abstract

The Polo-like kinases (Plks) are an evolutionary conserved family of Ser/Thr protein kinases that possess, in addition to the classical kinase domain at the N-terminus, a C-terminal polo-box domain (PBD) that binds to phosphorylated proteins and modulates the kinase activity and its localization. Plk1, which regulates the formation of the mitotic spindle, has emerged as a validated drug target for the treatment of cancer, because it is required for numerous types of cancer cells but not for the cell division in noncancer cells. Here, we employed chemical biology methods to investigate the allosteric communication between the PBD and the catalytic domain of Plk1. We identified small compounds that bind to the catalytic domain and inhibit or enhance the interaction of Plk1 with the phosphorylated peptide PoloBoxtide in vitro. In cells, two new allosteric Plk1 inhibitors affected the proliferation of cancer cells in culture and the cell cycle but had distinct phenotypic effects on spindle formation. Both compounds inhibited Plk1 signaling, indicating that they specifically act on Plk1 in cultured cells.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29927572     DOI: 10.1021/acschembio.7b01078

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  4 in total

1.  Inhibition of Polo-like Kinase 1 by HMN-214 Blocks Cell Cycle Progression and Inhibits Neuroblastoma Growth.

Authors:  Rameswari Chilamakuri; Danielle Crystal Rouse; Saurabh Agarwal
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-24

2.  A dimerization-dependent mechanism regulates enzymatic activation and nuclear entry of PLK1.

Authors:  Mourad Sanhaji; Klaus Strebhardt; Monika Raab; Yves Matthess; Christopher A Raab; Niklas Gutfreund; Volker Dötsch; Sven Becker
Journal:  Oncogene       Date:  2021-11-10       Impact factor: 9.867

3.  Development of a Novel Cell-Permeable Protein-Protein Interaction Inhibitor for the Polo-box Domain of Polo-like Kinase 1.

Authors:  David J Huggins; Bryn S Hardwick; Pooja Sharma; Amy Emery; Luca Laraia; Fengzhi Zhang; Ana J Narvaez; Meredith Roberts-Thomson; Alex T Crooks; Robert G Boyle; Richard Boyce; David W Walker; Natalia Mateu; Grahame J McKenzie; David R Spring; Ashok R Venkitaraman
Journal:  ACS Omega       Date:  2019-12-24

4.  Novel indolic AMPK modulators induce vasodilatation through activation of the AMPK-eNOS-NO pathway.

Authors:  Marta Sanz-Gómez; Elnaz Aledavood; Marina Beroiz-Salaverri; Laura Lagartera; Elena Vega-Martín; Marta Gil-Ortega; Jose Cumella; Concepción Pérez; Francisco Javier Luque; Carolina Estarellas; María S Fernández-Alfonso; Ana Castro
Journal:  Sci Rep       Date:  2022-03-10       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.